ArticleNature communications2019
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 52 citations in OpenAlex.
- Biocatalytic Nanoregulators Restore Joint Redox-Immune Homeostasis in Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable ROS modulation by nanomedicine for rheumatoid arthritis treatment.Materials today. Bio · 2026Review
- CD73 blockade alleviates collagen-induced arthritis by inhibiting synovial fibroblast activity.Iranian journal of basic medical sciences · 2026Article
- An aptamer specifically targeting mCRP ameliorates experimental arthritis.Journal of orthopaedic translation · 2025Article
- Therapeutic restoration of mitochondria-endoplasmic reticulum cross talk for osteoarthritis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Early prediction of bone destruction in rheumatoid arthritis through machine learning analysis of plasma metabolites.Arthritis research & therapy · 2025Article
- Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against αPD1-induced cardiotoxicity in mice.Nature communications · 2025Article
- The role of hypoxic microenvironment in rheumatoid arthritis.Frontiers in immunology · 2025Review
- Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt.Current drug targets · 2025Review
- Article
- Gut microbial metabolite targets HDAC3-FOXK1-interferon axis in fibroblast-like synoviocytes to ameliorate rheumatoid arthritis.Bone research · 2024Article
- Prodrug-based nanomedicines for rheumatoid arthritis.Discover nano · 2024Review
- Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Article
- Cold air plasma improving rheumatoid arthritis via mitochondrial apoptosis pathway.Bioengineering & translational medicine · 2023Article
- Liver-secreted fluorescent blood plasma markers enable chronic imaging of the microcirculation.Cell reports methods · 2022Article
- Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation.Nature communications · 2022Article
- Novel research synergized by Chinese medicine pattern classification in rheumatoid arthritis.Clinical rheumatology · 2022Article
- Epigenetic landscape of drug responses revealed through large-scale ChIP-seq data analyses.BMC bioinformatics · 2022Article
- Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice.Theranostics · 2022Article
- C-Reactive Protein Knockout Attenuates Temporomandibular Joint Inflammation in Rats.Journal of immunology research · 2022Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
18 authors at 3 institutions in 3 countries.
Chao LiangLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-5617-3483
Jie LiFaculty of Medicine, School of Chinese Medicine, Chinese University of Hong Kong, 999077, Hong Kong SAR, China.
Cheng LuLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Duoli XieLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Jin LiuLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Chuanxin ZhongLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Xiaohao WuLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Rongchen DaiLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Huarui ZhangLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Daogang GuanLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Baosheng GuoLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Bing HeLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Fangfei LiLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Xiaojuan HeLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Wandong ZhangThe First Affiliated Hospital of Anhui University of Chinese Medicine, 230031, Hefei, China.
Bao-Ting ZhangFaculty of Medicine, School of Chinese Medicine, Chinese University of Hong Kong, 999077, Hong Kong SAR, China.
Ge ZhangLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China. zhangge@hkbu.edu.hk.
Aiping LuLaw Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, 999077, Hong Kong SAR, China.
Hong Kong Baptist University · HKChinese University of Hong Kong · HKAnhui University of Traditional Chinese Medicine · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive bone erosion. Leflunomide is originally developed to suppress inflammation via its metabolite A77 1726 to attenuate bone erosion. However, distinctive responsiveness to Leflunomide is observed among RA individuals. Here we show that Leflunomide exerts immunosuppression but limited efficacy in RA individuals distinguished by higher serum C-reactive protein (CRP
Indexed as
AcriflavineAdultAnimalsArthritis, ExperimentalArthritis, RheumatoidAryl Hydrocarbon Receptor Nuclear TranslocatorBone ResorptionCells, CulturedCollagenC-Reactive ProteinFemaleHepatocytesHumansHypoxia-Inducible Factor 1, alpha SubunitImmunosuppressive AgentsLeflunomideAcriflavineAryl Hydrocarbon Receptor Nuclear TranslocatorCollagenC-Reactive ProteinHypoxia-Inducible Factor 1, alpha SubunitImmunosuppressive AgentsLeflunomideReceptors, Aryl HydrocarbonRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.